Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated December 11, 2024, details the results of Xenetic Biosciences, Inc.'s 2024 Annual Meeting of Stockholders. The Company is incorporated in Nevada and its common stock trades on The Nasdaq Stock Market under the symbol "XBIO."
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting. All proposals were approved by the requisite majority of votes cast.
- Proposal 1: Election of Directors. Six nominees were elected to the Board of Directors. Significant broker non-votes (391,780) were recorded for all director candidates.
- Proposal 2: Ratification of Auditors. Stockholders approved the selection of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Proposal 3: Executive Compensation (Say on Pay). Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers.
- Proposal 4: Say on Frequency. Stockholders approved, on a non-binding advisory basis, holding future advisory votes on executive compensation every 1 year.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors. The Company stated its intent to hold future advisory stockholder votes on executive compensation annually, consistent with the Board's recommendation and the "Say on Frequency" vote results.
Key Facts for Investor Verification
- Verify the total number of shares outstanding to contextualize the voting percentages and the high volume of broker non-votes (391,780) on director elections.
- Confirm the specific compensation details for named executive officers referenced in the "Say on Pay" proposal by reviewing the 2024 Proxy Statement.
- Review the Company's most recent 10-K or 10-Q filings for financial performance data, as this 8-K contains no financial metrics.
- Note that James Parslow signed the report as Interim Chief Executive Officer.